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Abstract
Background Little is known about the impact of hospi-
talization on antihypertensive pharmacotherapy and blood
pressure control in older persons.
Objectives The aim of this study was to explore the impact
of hospitalization on the management of hypertension and
antihypertensive pharmacotherapy in a cohort of older
patients with a documented diagnosis of hypertension.
Methods A retrospective, cross-sectional medical record
auditwas conducted in a largeAustralianmetropolitan teaching
hospital. Patients aged 65 years or older, admitted between
January 1st 2010 and December 31st 2010, and with a docu-
mented diagnosis of hypertension in their medical record were
included in the study. Antihypertensive pharmacotherapy and
blood pressure control was compared between admission and
discharge. Factors associated with changes to antihypertensive
pharmacotherapy were identified.
Results Changes to antihypertensive pharmacotherapy
occurred in 39.5 % (n = 135) of patients (n = 342). On
discharge, the proportion of patients receiving antihyperten-
sive pharmacotherapy (89.0 vs 85.3 %, p\ 0.0001) and the
mean number of antihypertensive agents per patient
(1.7 ± 1.1 vs 1.5 ± 1.1, p\ 0.0001) declined compared
with admission.Adverse drug reactions [odds ratio (OR) = 5,
95 % confidence interval (CI): 2.80–9.34] were the main
reason documented for antihypertensive pharmacotherapy
changes. Patients admitted under the care of medical
(OR = 0.3, 95 % CI: 0.17–0.70) or surgical (OR = 0.3,
95 %CI: 0.12–0.53) specialties were less likely to experience
changes to their antihypertensive pharmacotherapy than those
treated by gerontology or cardiology teams.
Conclusions Hospitalization has a significant impact on
antihypertensive pharmacotherapy. Two out of every five
older persons on antihypertensive medications will experi-
ence changes to their regimens during admission to hospital
with most changes in antihypertensive pharmacotherapy due
to adverse drug reactions.
Key points
Hospitalization has a considerable significant impact
on antihypertensive pharmacotherapy among older
populations.
Two out of every five older persons using
antihypertensive medications experienced changes to
their antihypertensive regimens during admission to
hospital.
Adverse drug reactions are an important factor
associated with changes to antihypertensive
pharmacotherapy during hospitalization for
antihypertensive medication changes, highlighting
the challenges in balancing the benefits and risks
associated with the use of these medications in older
persons.
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1 Introduction
Hypertension is a major risk factor for cardiovascular
disease, cerebrovascular disease, and non-cardiovascular
complications [1–3]. It is a common chronic condition
affecting up to 70 % of the Australian adult population [4,
5]. Hypertension affects three-quarters of the older adult
population with a seven-fold higher annual incidence in
older compared with younger adults [6]. Pharmacotherapy
using a single or a combination of several antihypertensive
medications has a pivotal role in the long-term manage-
ment of hypertension and the prevention of associated
morbidity and mortality [7]. Multiple meta-analyses of
large well-conducted clinical trials have demonstrated the
benefits of pharmacotherapy in the management of hyper-
tension among older and very old populations [8–10].
However, several studies have reported the persistence of
suboptimal blood pressure (BP) control among older per-
sons [11, 12].
Although older adults represent only 13 % of the Aus-
tralian population, approximately four out of every ten
hospital admissions are for older persons, and persons aged
over 65 years account for 50 % of patient bed days [13].
As a common chronic condition, hypertension is routinely
managed in the community [4, 5]. Regular patient review is
essential for the management of any chronic condition and
can improve patient outcomes. While transitions of care
such as hospitalization are often associated with changes in
patient care, transitions of care involving changes to
medication regimens may represent an opportunity to
improve BP control. However, it may also adversely
impact BP control associated with changes that may occur
during patient hospitalization.
Hospitalization has been reported to have a significant
impact on long-term medication use [14]. In the acute care
setting, patients with multiple morbidities are managed by
multidisciplinary-care teams [15]. Management priorities
and treatment goals during hospitalization may be very
different to those in primary care. While multidisciplinary
care is the ideal for all healthcare, current acute care set-
tings tend to be specialty based, with patients treated by a
healthcare team appropriate for their primary presentation.
In this context, the control of chronic comorbid conditions
such as hypertension may be considered a lower priority.
However, little is known about the impact of hospitaliza-
tion on antihypertensive therapy and BP control among
older persons. Therefore, the aim of this study was to
explore the impact of hospitalization on hypertension
management in older patients. The main objectives of the
study were to determine the frequency of changes to anti-
hypertensive medications during hospitalization, the type
of changes made, how the changes impact BP control, and
to identify risk factors associated with antihypertensive
medication changes in a cohort of older patients with a




Patients aged 65 years and over, admitted to a large
Australian tertiary metropolitan teaching hospital between
January 1st 2010 and December 31st 2010, with a doc-
umented diagnosis of hypertension in their medical record
were eligible for inclusion in the study. To identify eli-
gible patients, a systematic sampling of every ninth
admission throughout the study period was used to ensure
that admissions were distributed evenly throughout the
year and to overcome any potential seasonal clustering.
To allow for adequate medical documentation, only
admissions with a duration of at least 48 h were included
in the sample. For patients with multiple admissions
during the study period, only the first admission was
included in the study. Patients admitted outside the study
period, those who did not have a documented diagnosis of
hypertension, those for whom the medical records could
not be accessed, and those aged less than 65 years were
excluded from the study (n = 156).
2.2 Study Design and Covariates
A retrospective, cross-sectional medical records audit was
conducted. Data were extracted from the medical records
by a single trained researcher using a pre-defined case
record form. All documentation associated with the
admission including medical record, drug charts, medical
referral letters, hospital admission summary, laboratory
reports, pharmacists’ note, and medication history and
reconciliation form, nursing progress notes, adverse drug
reactions (ADRs) summary sheet, and the discharge sum-
mary report were reviewed for data collection.
Data collected included demographic information,
medical history including documented information on rel-
evant comorbidities, prescribed medications, BP control,
and documented diagnosis of either current or a docu-
mented history of hypertension on admission. Frailty was
determined using the Rockwood scale [16]. Frailty was
converted to a dichotomous variable with fit older persons
considered as those with a frailty index (score = 0) and
frail patients as those with a (score C 1) [16]. Comorbidity
burden was calculated using the Charlson age-adjusted
Comorbidity Index [17].
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2.3 Antihypertensive Pharmacotherapy
Antihypertensive medications were defined as those med-
ications recommended for the management of hypertension
according to the current National Guideline for the Man-
agement of Hypertension [18]. Medicines were coded
according to the World Health Organization Anatomic
Therapeutic Chemical (ATC) classification system. Anti-
hypertensive medications included angiotensin-converting
enzyme inhibitors (ACEI) and angiotensin-II receptor
blockers (ARB, ATC C09), calcium channel blockers
(CCB, ATC C08), beta blockers (BB, ATC C07) with the
exception of sotalol (C07AA07), thiazide and thiazide-like
diuretics (ATC C03A, C03B, and C03E), and other anti-
hypertensives (ATC C02), namely methyldopa, moxoni-
dine, prazosin, terazosin, clonidine, and hydralazine.
Fixed-dose combination products were considered as two
separate medications.
2.4 Antihypertensive Medication Changes
Medication use on admission, discharge, and at the time of
any actual or potential ADR was recorded. Medication lists
on admission were compared with medications on dis-
charge. Differences in antihypertensive medications
between the two lists were classified as changes. Changes
were then further classified into one of the following
mutually exclusive categories: medication commenced,
medication ceased, dose increased, dose decreased, or a
substitution of a different agent from the same therapeutic
class. For each identified change, documented reasons for
antihypertensive medications changes were recorded.
Reasons for medication changes were considered undocu-
mented if there was no reason recorded for the medication
change in the medical record.
2.5 Hypertension and Blood Pressure Control
Patients were considered to be at target BP control if they met
the current Australia National Guideline for the Management
of Hypertension [18]. Comorbidities were taken into consid-
eration for individual patients as specified by the guideline
[18]. According to the current Australian guideline, the
treatment target for patients with no relevant comorbid con-
ditions is\140/90 mmHg or lower if tolerated, and for those
with coronary heart disease, diabetes mellitus, chronic kidney
disease, proteinuria, or stroke/transient ischemic attack, the
target is\130/80 mmHg. [18].
2.6 Adverse Drug Reactions Causality Assessment
ADRs were defined according to the World Health Orga-
nization definition [19]. Potential ADRs were identified in
two ways. ADRs that had been detected and documented
by the patients’ treating team were identified from the
medical records, while a trigger list based on published
literature was developed to aid in the identification of
potential ADRs that had not been documented in the
medical record. The causal relationship between each
potential ADR and the suspected medications was assessed
using the Naranjo algorithm [20].
2.7 Study Outcomes
The main study outcomes were changes to the antihyper-
tensive medication regimen and factors predicting changes
in hypertension therapy in older patients with hypertension
admitted to an acute care setting.
2.8 Statistical Analysis
Data were entered into a custom-built Microsoft Access
database for manipulation and analysis was performed
using SPSS statistics (Version 20). Continuous variables
were presented as means and standard deviation (±SD) for
normally distributed variables and median and interquartile
range (IQR) for those that did not have a normal distri-
bution. Categorical variables were presented as frequencies
and percentages. Univariate analyses (t test, Chi-squared
test, McNemar’s test) were used to test the difference in the
sampling distributions of continuous and categorical vari-
ables as appropriate. Variables with a p value\0.1 and at
least 10 patients in case or outcome variables were inclu-
ded in the binary logistic regression model to examine for
associations between changes to antihypertensive medica-
tion, and this included the following independent variables;
length of hospital stay, treating specialty, number of
comorbidities, specified comorbidities, number of antihy-
pertensive medications on admission, type of prescribed
antihypertensive medication on admission, ADRs. Age and
sex were forced into all models as we were interested in
examining the impact of patient sex and age and hyper-
tension medication changes. Multicollinearity assumptions
were also checked using a tolerance of[0.1 and variance
inflation factors\5. All statistical tests were performed at a
significance level of a = 0.05 and a 95 % confidence
interval (CI).
3 Results
Medical records of 503 patients were reviewed and of these
347 (69.0 %) had a documented diagnosis of hypertension
included in their medical record and were included in this
study. Patients with a documented diagnosis of hyperten-
sion were significantly older than those without and there
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was a higher proportion of female patients (Table 1). The
majority of patients were admitted for non-cardiovascular
conditions and only three patients were admitted primarily
for the management of hypertension
On hospital admission, BP was considered controlled in
128 (36.9 %) of the patients with a documented diagnosis
of hypertension. Data on BP and BP control prior to the
current admission was documented in the medical record
for 57 patients (16.4 %). Of those with prior BP control




Medication lists on admission represent all medications
taken prior to hospitalization. Most patients with a docu-
mented diagnosis of hypertension were receiving at least
one antihypertensive medication prior to hospitalization.
Only 39 (11.2 %) were not using any antihypertensive
pharmacotherapy on admission.
The most commonly prescribed antihypertensive agents
were ARB (38.9 %), ACEI (37.5 %), and CCB (35.4 %)
(Table 1). Approximately one third of patients were on
monotherapy (n = 131, 38 %), with a further 31.0 %
(n = 107) of hypertension patients on dual therapy and 20.0 %
(n = 70) on three or more antihypertensivemedications. Fifty-
seven patients (18.2 %) were using a fixed-dose antihyperten-
sive combination therapy, and the most common fixed-dose
combinations were ARB/hydrochlorothiazide (n = 37,
11.8 %) and ACEI/hydrochlorothiazide (n = 10, 3.2 %).
3.2 Changes to Antihypertensive Pharmacotherapy
During hospitalization, 135 (38.9 %) patients with hyper-
tension experienced changes to their antihypertensive
medication regimen. On discharge, the proportion of
patients with a diagnosis of hypertension who were
receiving an antihypertensive agent had declined compared
to admission (89.0 vs 85.3 %, p\ 0.0001). In addition, the
mean number of antihypertensive agents per patient had
also declined (1.5 ± 1.1 vs 1.7 ± 1.1, p\ 0.0001).
On discharge, ACEI (34.5 %) and CCB (32.3 %) were
the most commonly prescribed agents followed by BB
(31.6 %), ARB (31.6 %), thiazide diuretics (13.7 %), and
other antihypertensive agents (4.7 %). More patients were
discharged on monotherapy (42.4 vs 38 %, p = 0.02),
while the proportion of patients on dual antihypertensive
medications (28.9 vs 31.0 %, p = 0.36) or three or more
antihypertensive medications (15.4 vs 20.0 %, p = 0.003)
had declined on discharge. Fewer patients were using
fixed-dose antihypertensive combination preparations (10.4
vs 18.2 %, p\ 0.0001).
The most common change overall was medication ces-
sation. In total, 79 medications were ceased, representing
43.9 % of the total changes. Cessation was also the most
common change for each individual drug class. The next
most common change was commencement of new anti-
hypertensive medications.
Changes to fixed-dose combination therapy were
observed in 21 patients, with the most prevalent change a
cessation of fixed-dose therapy and commencement of
single-dose therapy (n = 16) or cessation of fixed-dose
therapy and the patient discharged on no antihypertensive
medications (n = 5). The most commonly used fixed-dose
combinations did not change with 8.1 % of patients using
ARB/hydrochlorothiazide and 2.0 % using ACEI/hy-
drochlorothiazide on discharge.
On admission, 126 (36.8 %) of all patients with a doc-
umented diagnosis of hypertension were at their target BP
level. Upon discharge, this figure had increased to 72.0 %
(n = 250). Of the 126 patients who had controlled BP on
admission, 49 patients (38.9 %) experienced changes to
their antihypertensive medications. Fifteen patients who
were controlled on admission and experienced changes to
their medications were not controlled on discharge. Out of
216 patients with uncontrolled BP on admission, 86
(39.8 %) experienced changes to their antihypertensive
medications during their admission. Just under half of these
(42.1 %) were then at the target BP level at discharge.
3.3 Reasons for Antihypertensive Medication
Changes
The main reason for antihypertensive medication changes
was suspected ADRs (Table 2). ADRs, where one or more
antihypertensive medications were considered causal
agents on Naranjo assessment, were significantly associ-
ated with changes in antihypertensive medications
(p\ 0.001). In general, the reasons for antihypertensive
medication changes were documented in the patients’
records, although no documented reason was available for
antihypertensive medication changes in 16 patients
(11.9 %).
3.4 Factors Associated with Changes
in Antihypertensive Medications
On univariate analysis, use of BB or ARB on admission,
past or current history of myocardial infarction, admission
under cardiology and geriatric treating specialties, occur-
rence of an ADR during admission, longer length of stay,
higher number of antihypertensive medications, impaired
renal function (estimated glomerular filtration rate,
increased number of comorbidities and comorbid angina,
atrial fibrillation, or chronic kidney disease were all
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associated with antihypertensive medication changes
(Table 3). Other factors such as smoking, alcohol con-
sumption, living status, number of medications used on
admission, use of other antihypertensive classes, patients
on fixed-dose combination or patients using two or more
antihypertensive medications of the same class, patients
with hyper/hypotension episodes during hospital stay, non-
mechanical falls, frailty, and patients with comorbid con-
ditions (congestive heart failure, hyperlipidemia, chronic
airway disease, asthma, dementia, depression, cancer
patients, gout, thyroid disorder) were not associated with
medication changes on univariate analysis.
Table 1 Characteristics of the study population on admission (n = 503). Variables are presented as mean (±SD), median (±IQR), or number
(%)
Patients with a documented history of
hypertension (n = 347)
Patients without a documented history of
hypertension (n = 156)
p value
Mean age (years) 81.0 (±8.4) 78.7 (±7.8) 0.004
Number of women 209 (60.2) 86 (55.1) 0.284
No. living at home prior to admission 288 (83.0) 127 (81.4) 0.703
No. fit (non-frail) 183 (52.7) 86 (55.1) 0.630
Mean systolic BP on admission 143.5 (±26.5) 132.9 (±21.3) 0.000
Mean diastolic BP on admission 76.0 (±713.7) 73.1 (±11.1) 0.014
No. per treating specialty
Surgical 99 (28.5) 46 (29.5) 0.832
Medical 112 (32.4) 59 (37.8) 0.263
Cardiology 83 (23.9) 86 (16.7) 0.079
Gerontology 31 (8.9) 12 (7.7) 0.732
Other 22 (6.3) 13 (8.3) 0.450
Mean estimated glomerular filtration
rate (mL/min)a
62.5 (±21.7) 71.0 (±18.2) 0.000
Median Charlson Comorbidity Index 2.0 (±2.0) 2.0 (±3.0) 0.868
Number with comorbid condition
Angina 48 (13.8) 11 (7.1) 0.035
Atrial fibrillation 84 (24.2) 24 (15.4) 0.026
Myocardial infarction 100 (28.8) 21 (13.5) 0.000
Congestive heart failure 45 (13.0) 15 (9.6) 0.303
Depression 48 (13.8) 21 (13.5) 1.000
Dementia 33 (9.5) 20 (12.8) 0.168
Hyperlipidemia 141 (40.6) 33 (21.2) 0.000
Diabetes mellitus 60 (17.3) 13 (8.3) 0.009
Current smoker 21 (6.3) 12 (7.7) 0.569
Regular alcohol intake 114 (32.9) 55 (35.3) 0.611
Overweight or obese (body mass
index C25 kg/m2)
125 (36.0) 34 (21.8) 0.029
Median number of medications 8.0 (±6.0) 5.0 (±5.0) 0.000
Median number of antihypertensive
medications
2.0 (±1.0) 0.0 (±0.0) 0.000
Number using each antihypertensive medication class on admission
ACEI 130 (37.5) 9 (5.8) 0.000
ARB 135 (38.9) 3 (1.9) 0.000
BB 107 (30.8) 14 (9) 0.000
CCB 123 (35.4) 7 (4.5) 0.000
Thiazide and thiazide-like diuretics 71 (20.5) 1 (0.6) 0.000
Other antihypertensives 20 (5.8) 1 (0.6) 0.007
BP blood pressure, ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, BB beta blocker, CCB calcium channel
blocker, SD standard deviation, IQR interquartile range
a Estimated glomerular filtration rate using the MDRD equation
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All factors associated with antihypertensive medication
changes on univariate analysis where the number of cases
was 10 or greater were included in the multivariate model.
In the multivariate model, only being treated by cardiology
or gerontology specialties, use of a BB or ARB, and a past
or current history of myocardial infarction remained sig-
nificantly associated with antihypertensive medication
changes (Table 3).
Table 2 Reasons for changes
to antihypertensive medications
during hospital admission for
patients with a documented
diagnosis of hypertension
(n = 342)
Reasons for changes No. of patients (%a)
Adverse drug reaction 52 (38.5)
Hypotension 33 (24.4)
Renal impairment or increased risk of renal injury 23 (17.0)
Poor BP control 21 (15.6)
Electrolyte disturbance 11 (8.1)
Cardiovascular comorbidities (Angina/MI/CHF) 11 (8.1)
Rhythm disturbance 9 (6.7)
Falls risk 4 (3.0)
Cerebrovascular accident 3 (2.2)
Peripheral edema 3 (2.2)
BP considered controlled 2 (1.5)
Non-adherence 1 (0.7)
Palliative care 1 (0.7)
Gout risk 1 (0.7)
BP blood pressure, MI myocardial infarction, CHF congestive heart failure
a Total does not sum to 100 % because patients may have multiple reasons contributing to each change










Factors Unadjusted OR (95 % CI) Adjusted ORa (95 % CI)
Age (years) 1.0 (0.99–1.05) 1.0 (0.96–1.03)
Sex 0.7 (0.43–1.05) 0.7 (0.41–1.29)
Length of stay (days) 1.0 (1.01–1.06) 1.0 (0.99–1.05)
Treating specialty
Cardiology 2.7 (1.63–4.5) b
Medical 0.5 (0.27–0.84) 0.3 (0.17–0.70)
Surgical 0.2 (0.12–0.44) 0.3 (0.12–0.53)
Geriatric 0.8 (0.34–1.78) 0.7 (0.23–1.84)
Other 0.1 (0.04–0.60) 0.1 (0.03–0.60)
Mean no. of antihypertensive medications 1.4 (1.17–1.77) 1.2 (0.91–1.63)
ARB 1.6 (1.00–2.43) 1.2 (0.70–2.21)
BB 3.0 (1.84–4.77) 2.1 (1.08–4.00)
ADR 5.2 (3.13–8.44) 5.1 (2.80–9.34)
No. of comorbidities 1.1 (1.00–1.22) 0.9 (0.79–1.07)
eGFR 0.9 (0.97–0.99) 1.0 (0.98–1.02)
Angina 2.11 (1.14–3.93) 1.49 (0.68–3.29)
MI 2.33 (1.44–3.75) 2.09 (1.07–3.79)
AF 2.79 (1.46–5.36) 1.35 (0.72–2.56)
CKD 2.08 (1.26–3.44) 2.041 (0.85–4.91)
OR odds ratio, ARB angiotensin receptor blocker, BB beta blocker, ADR adverse drug reaction, eGRF
estimated glomerular filtration rate, MI myocardial infarction, AF atrial fibrillation, CKD chronic kidney
disease, CI confidence interval
a Adjusted for age, sex, length of stay, treating specialty, number of antihypertensive medications, ARB,
BB, ADR, number of comorbidities, renal function, angina, MI, AF, and CKD
b Cardiology used as the reference
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4 Discussion
This is the first study internationally to demonstrate that
changes to antihypertensive medications occur frequently
for older patients with comorbid hypertension during hos-
pitalization. Cessation was the most common change to
antihypertensive pharmacotherapy observed. ADRs were
the primary reason for antihypertensive changes, high-
lighting the challenges in balancing the benefits and risks
associated with the use of these medications in older
persons.
Findings from our study show that changes to antihy-
pertensive pharmacotherapy among older inpatients were
common, echoing findings of previous studies [21, 22].
Similar to findings by Wang et al. [23] we found that the
number of antihypertensive medications decreased fol-
lowing hospitalization. While ACEI were the most com-
monly prescribed antihypertensive agent on discharge there
was a noticeable decline in both ACEI and ARB use fol-
lowing hospitalization. Potential concerns regarding
increased risks of side effects such as hypotension, risk of
renal injury, and electrolyte disturbances in older persons
may be important factors for this. However, both ACEI and
ARBs are considered effective agents in the management
of hypertension among older adults, particularly in diabetic
patients with hypertension, and in general are well toler-
ated in older patients [24, 25].
In our study, CCB were the second most common
antihypertensive class used at discharge. CCB are often
recommended second line after diuretics for the manage-
ment of hypertension in older individuals, [26, 27] which
may be because of perceived high tolerability of CCB in
older persons [29] and their role in the management of
isolated systolic hypertension [28]. Our findings show a
considerably high use of BB, which may be explained by
the efficacy of BB in hypertension management in patients
with certain cardiovascular indications such as ischemic
heart disease. Commencement was the most common
change associated with BB in our study in patients with a
past or current history of MI during hospital admission.
Increasing use of BB was also reported by a recent US
study [30]. In the US study, BB use increased from 12.7 to
43.1 % (p\ 0.001).
An association between the treating specialty and
changes in antihypertensive medications was observed in
our study. Despite only three patients admitted primarily
for the management of hypertension, patients admitted
under the care of cardiology and geriatric teams were more
likely to experience changes to their antihypertensive
regimens than those managed by medical or surgical teams.
De-prescribing by geriatric teams and the management of
associated cardiovascular conditions for which
antihypertensive medications are indicated may underlie
this finding. Other studies have also found that manage-
ment of very old individuals is influenced by the specialty
of the treating healthcare professional [31] with one study
reporting that cardiologists were more likely to more
comprehensively document ADR and patients medication
adherence compared with other specialties [32], both of
which were common reasons for medication changes
observed in this study.
On admission to hospital, a little over half of the older
individuals in this cohort with a current or past documented
diagnosis of hypertension were at target BP levels. This
percentage increased on discharge to over 70 %, high-
lighting that while the main medication change was ces-
sation of antihypertensive agents, BP control improved
during hospitalization. Interestingly, the potential under-
treatment of older individuals may also be an issue, with
almost 10 % of patients who were not at the target level on
admission, having experienced no changes to their medi-
cations and still not being at the target level upon dis-
charge. Such under-treatment may warrant further
investigation, especially given a study by Maronde et al.
that found that underuse of antihypertensive medications
following hospital discharge was associated with an
increased risk of re-hospitalization [33].
In this study, we found that suspected and actual ADRs
were the main reason associated with a change to antihy-
pertensive medications among older patients. Earlier
studies have reported that antihypertensive medications are
a risk factor for ADRs in general adults, in both the hos-
pital and ambulatory settings [34, 35] and it has been
shown that older individuals have a higher risk of experi-
encing an ADR [36]. However, the size of the risk of
antihypertensive-related ADRs in older individuals remains
unknown and requires further investigation. ADRs can
strongly impact hypertension management and be associ-
ated with discontinuation of therapy, [37] leading to sub-
sequent suboptimal BP control [38] and may limit any
further required interventions to achieve optimal BP [39].
Thus, further work exploring the risk of antihypertensive
ADRs in older populations is needed.
This study has certain limitations, which may affect
interpretation of the findings. One limitation was the use of
documentation in the medical records to identify persons
with hypertension that may have resulted in misclassifica-
tion of individuals depending on the documentation accu-
racy. A second limitation was the limited number of patients
per variable in the logistic model owing to the exploratory
nature of the work. Further work using a large representative
sample is needed to confirm the relationships observed in
this study. Finally, hospitalization may affect BP control and
very limited information on long-term control was available
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for this study. The main strength of this study was the
observational design that allowed changes in antihyperten-
sive pharmacotherapy occurring in actual clinical practice to
be quantified. Furthermore, this study examined a range of
specialties rather than just focusing on patients with hyper-
tension admitted under cardiologists.
5 Conclusion
Hospitalization has a significant impact on antihyperten-
sive pharmacotherapy. Two out of every five older persons
taking antihypertensive medications will experience chan-
ges to their regimens during admission to hospital. While
such changes were associated with improved BP, the
association between medication changes, ADRs, and other
side effects observed in this cohort highlights the need for
patient education and better/increased communication with
other healthcare professionals regarding medication chan-
ges during hospitalization.
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